Clinical trials: Vascular Thrombosis
Venous Thromboembolism (VTE), Intensive Care Medicine
Pulsed Electromagnetic Field Therapy or Pneumatic Compression VTE Prophylaxis
Venous thromboembolism (VTE) is frequent in patients in the intensive care unit (ICU). Pharmacologic prophylaxis is sometimes contraindicated, and mechanical prophylaxis is used.
- Conditions
- Venous Thromboembolism (VTE), Intensive Care Medicine, Venous Thromboembolism
- Trial name
- SOPHIE (NCT06958588)
- Testing
- Experimental: Hyperslim, Active Comparator #1
- Where
- Brazil
- Volunteers
- 50 people
- Sponsor
- Science Valley Research Institute
Hemodialysis Catheter Blood Stream Infection, Central Line Infection
Randomised Controlled Trial of Needle Free Access Devices in Preventing Hemodialysis Blood Stream Infection
This study will be a randomised controlled trial examining whether a new type of needle free access device(TEGO) is associated with less episodes of infection of dialysis lines, when compared to the current gold standard.
- Conditions
- Hemodialysis Catheter Blood Stream Infection, Central Line Infection, Dialysis Line Thrombosis
- Trial name
- TEGO (NCT01082770)
- Testing
- TEGO, Standard
- Where
- Ireland
- Volunteers
- 106 people
- Sponsor
- Beaumont Hospital
Cancer-associated Thrombosis, Genetic Predisposition
A New Clinic-Genetic Risk Score for Predicting Venous Thromboembolic Events in Cancer Patient
Venous thromboembolism (VTE) is a common disease in cancer patients and one of the major causes of cancer-associated mortality. Risk for developing VTE increases when cancer patients are receiving chemotherapy.
- Trial name
- ONCOTHROMB (NCT03114618)
- Where
- 9 sites in Spain
- Volunteers
- 416 people
- Sponsor
- Andres muñoz
Intracardiac Thrombus, Intracardiac Mass
AngioVac Aspiration Therapy Registry
As a structured, multinational retrospective registry the AVATAR Registry addresses the following scientific aspects through systematic data collection, centralized quality control, and robust statistical analysis in patients…
- Conditions
- Intracardiac Thrombus, Intracardiac Mass, Intravascular Thrombosis, Vegetation; Heart
- Trial name
- AVATaR (NCT07769320)
- Testing
- Retrospective analysis of assigned treatment
- Where
- Germany
- Volunteers
- 1,000 people
- Sponsor
- Charite University, Berlin, Germany
Cancer, Venous Thromboembolism
Allo - Cancer - Thrombosis
Management of venous thromboembolism (VTE) in patients with cancer is complex and require the intervention of many specialized health professionals, in hospital but also at home and during follow-up.
- Trial name
- AlloTC (NCT03563924)
- Testing
- Setting up a specific care path "AlloTC" for management of TVE in patients with cancer
- Volunteers
- 100 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Retinal Vein Occlusion, Posterior Vitreous Detachment
Posterior Vitreous Detachment (PVD) Assessment During Dual Retinal Vein Occlusion (RVO) Lucentis Evaluations
This is a study of subjects with retinal vein occlusion (RVO) specifically looking at the difference in outcomes between patients with posterior vitreous detachment (PVD) and those without PVD.
- Trial name
- PADDLE (NCT00831350)
- Testing
- Ranibizumab
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Barnes Retina Institute
Retinal Artery Occlusion, Retinal Vein Occlusion
Changes in the Diameter of Retinal Vessels After Remote Ischemic Conditioning
Remote ischemic conditioning (RIC) is a therapeutic strategy for protecting organs or tissue against the detrimental effects of acute ischemia-reperfusion injury.
- Trial name
- NCT02898480
- Testing
- Remote ischemic conditioning
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- University of Aarhus
Pulmonary Embolism, Deep Vein Thrombosis
Safety Study of the Angel™ Catheter in Subjects With Risk of Pulmonary Embolism
The Angel™ Catheter combines the functions of a vena cava filter and a multi-lumen central line catheter. The device is designed to be placed in the inferior vena cava via the femoral vein for the prevention of Pulmonary Embolism…
- Conditions
- Pulmonary Embolism, Deep Vein Thrombosis, Venous Thromboembolism
- Trial name
- NCT01403090
- Testing
- Angel Catheter
- Where
- 2 sites in Colombia
- Volunteers
- 8 people
- Sponsor
- BiO2 Medical
Aortic Valve Replacement, Antithrombotic Therapy
Apixaban for the Prevention of Latent Biological Valve Thrombosis
Background: The optimal antithrombotic strategy early after aortic valve replacement surgery with a biological valve remains controversial due to lack of high-quality evidence.
- Conditions
- Aortic Valve Replacement, Antithrombotic Therapy, Bioprosthetic Valve Thrombosis, Rapid Deployment Valves
- Trial name
- NCT06184113
- Testing
- Aortic valve replacement surgery, Computed tomography, Echocardiography
- Where
- Croatia
- Volunteers
- 166 people
- Sponsor
- Clinical Hospital Centre Zagreb
Pulmonary Embolism, Acute Pulmonary Embolism
Thrombolysis Endovascular Treatment of Pulmonary Embolism
To assess the efficacy and safety of endovascular thrombolysis of pulmonary embolism with right ventricular dysfunction with single-dose rtPA
- Trial name
- STEP (NCT03966079)
- Testing
- recombinant tissue plasminogen activator
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Beijing Tsinghua Chang Gung Hospital
ST-segment Elevation Myocardial Infarction (STEMI), Left Ventricular Thrombus
Anti-CoagulaTion on Left Ventricular Thrombus After ST Segment Elevation Myocardial Infarction
Contemporary data are lacking regarding the management of left ventricular thrombus (LVT) developed after ST segment elevation myocardial infarction
- Trial name
- ACTonLVT (NCT05892042)
- Testing
- Rivaroxaban 15 MG [Xarelto]
- Where
- China
- Volunteers
- 320 people
- Sponsor
- Jilin University
Pulmonary Embolism (Diagnosis)
Mangement of Pulmonary Emboli
To assess to which extent we are adherent to ESC guidelines 2019 in management of patients presented with acute pulmonary embolism
- Trial name
- NCT06756373
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Assiut University
Retinal Vein Occlusion (RVO)
Robotic RVO Trial: Robot-assisted Retinal Vein Cannulation in Patients With Retinal Vein Occlusions
Retinal vein occlusions (RVOs) are the second leading cause of permanent vision loss in the UK. Current treatments, like anti-VEGF injections or steroids, address complications such as macular fluid but do not target the…
- Trial name
- RVO (NCT07820761)
- Testing
- Surgery with Preceyes Robot plus NHS standard of care
- Where
- United Kingdom
- Volunteers
- 40 people
- Sponsor
- University of Oxford
Systemic Sclerosis, Raynaud Phenomenon
Early Diagnosis of SSc in the General Rheumatology Clinic - Pilot
The goal of this observational pilot data acquisition study is to establish if target users can obtain diagnostic quality images in the clinic, from participants with Systemic Sclerosis (SSc), and SSc spectrum conditions.
- Trial name
- NCT06291142
- Testing
- Observation - Nailfold capillaroscopy
- Where
- United Kingdom
- Volunteers
- 112 people, healthy volunteers welcome
- Sponsor
- University of Manchester
Impaired Wound Healing, Factor XIII Deficiency
Wound Healing Abnormalities in Major Abdominal Surgery
This clinical observational study investigates the incidence of wound healing abnormalities in patients undergoing major abdominal surgery.
- Trial name
- INWOUND (NCT00735579)
- Where
- Germany
- Volunteers
- 260 people
- Sponsor
- Klinikum St. Georg gGmbH
Sickle Cell Disease, Venous Thromboembolism
Comparison of Thrombin Generation, Platelet Activation and Aggregation Profiles in Patients With Sickle Cell Disease Depending on Their SS or SC Genotype (DrepAgreg)
Sickle cell disease (SCD) is characterized by chronic hemolytic anemia, painful crises called vaso-occlusive crises (VOC) and chronic inflammation.
- Trial name
- DrepAgreg (NCT07852442)
- Where
- 2 sites in France, Guadeloupe
- Volunteers
- 60 people
- Sponsor
- Centre Hospitalier Universitaire de la Guadeloupe
Pulmonary Embolism, Hematopoiesis
Is Clonal Hematopoiesis of Indeterminate Potential Associated With Unprovoked Pulmonary Embolism?
The clonal hematopoiesis of indetermined prognosis (CHIP) has been described as risk factor for juvenile atherosclerosis. Moreover, some of CHIP genes are responsible of myeloproliferative disorders.
- Trial name
- HEMEP (NCT04711746)
- Testing
- blood sample
- Where
- France
- Volunteers
- 544 people
- Sponsor
- Centre Hospitalier Universitaire, Amiens
Venous Thromboembolism, Cancer
Tinzaparin for Primary Treatment and Extended Secondary Prophylaxis of Venous Thromboembolism in Patients With Cancer
In this study the investigators will determine the safety and effectiveness of Tinzaparin in preventing blood clots for up to 12 months of treatment.
- Trial name
- NCT00981903
- Testing
- Tinzaparin sodium
- Where
- 2 sites in United States
- Volunteers
- 131 people
- Sponsor
- University of Southern California
Raynaud's Disease
Safety, Tolerability, and Pharmacodynamic Profile of Oral 2101 in Secondary Raynaud's Disease
To investigate the severity of secondary Raynaud's disease-related attacks during the 14 days 2101 dosing period.
- Trial name
- NCT00528242
- Testing
- SLx-2101
- Where
- Germany
- Volunteers
- 17 people
- Sponsor
- Response Pharmaceuticals
Pulmonary Embolism, Pulmonary Thromboembolism
Recombinant Streptokinase Versus Urokinase in Pulmonary Embolism in China (RESUPEC)
Recombinant streptokinase (r-SK) is an effective thrombolytic agent developed with gene engineering. Its characteristics of high output and low production cost make it affordable in treating acute myocardial infarction (AMI) in…
- Trial name
- RESUPEC (NCT00968929)
- Testing
- Recombinant Streptokinase, Urokinase
- Where
- 8 sites in China
- Volunteers
- 83 people
- Sponsor
- Beijing Chao Yang Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.